See stories of people with tardive dyskinesia (TD) and how treatment with INGREZZA® helped. See PI, including Boxed Warning, and Med Guide.

INGREZZA (VALBENAZINE TOSYLATE): Valbenazine is used to treat involuntary movements of the face, tongue, or other body parts (tardive dyskinesia). This medication is thought to work by …

Explore clinical trial patient cases showing the results of INGREZZA treatment in adults with tardive dyskinesia. See Prescribing Info, including Boxed Warning.

Ingrezza (in-GREH-zah) was approved in 2017 as the first medicine to help control movement in people with tardive dyskinesia and was approved for use in people with chorea caused by …

May 7, 2025 · Our goal for ConnectING with Carnie is to reduce stigma, increase understanding and encourage individuals with involuntary movements to consult a healthcare provider for …

Feb 28, 2025 · Importantly, patients reported significant improvements across measures regardless of their underlying psychiatric conditions or the baseline severity of their TD …

Approved Uses INGREZZA® (valbenazine) capsules or INGREZZA® SPRINKLE (valbenazine) capsules are prescription medicines used to treat adults with: movements in the face, tongue, …

Jun 4, 2024 · In April 2024, the agency approved Ingrezza Sprinkle, an oral granule formulation of the medication for the same indication. By inhibiting VMAT2, the protein responsible for …

Dec 19, 2023 · INGREZZA Significantly Reduced the Symptoms of Involuntary Movements in Patients with Bipolar or Major Depressive Disorder in Post-Hoc Analysis. Patients Treated with …

Nov 26, 2025 · Learn about the FDA-approved treatment for tardive dyskinesia, specifically the VMAT2 inhibitors valbenazine (Ingrezza) and deutetrabenazine (Austedo).